Valneva: "on track" with Chikungunya vaccine after positive data

[December 05, 2022]  PARIS (Reuters) - Vaccines company Valneva on Monday reported positive 12-month antibody persistence data for its single-shot Chikungunya vaccine candidate.

The firm said in a statement it was currently on track to complete its submission for license application with the U.S. Food and Drug Administration (FDA) by the end of the year.

Chikungunya is a viral disease transmitted to humans by infected mosquitoes that causes fever as well as muscle and joint pain. There is currently no vaccine or specific drug against the virus.

The logo of French-Austrian biotech firm Valneva is seen outside their headquarters in Vienna, Austria, December 16, 2021. REUTERS/Lisi Niesner

(Reporting by Tassilo Hummel; Editing by Sudip Kar-Gupta)

[© 2022 Thomson Reuters. All rights reserved.]  This material may not be published, broadcast, rewritten or redistributed.  Thompson Reuters is solely responsible for this content.